logo

Haemonetics (HAE) : Trading Transparency
By: Bobs Advice for Stocks   Tuesday, May 05, 2009 9:13 AM

Vote for next session
The next market session will close:

Today Haemonetics (HAE), one of the six holdings in my trading account, announced 4th quarter results.  Revenue for the quarter rose 10% to $152.4 million.  Excluding items the company earned $.65/share.  Analysts had been expecting $.63/share so the company beat expectations on earnings. Analysts had been expecting $151.1 million according to Reuters estimates; thus the company beat on revenue as well.  The company went ahead and guided pretty much to expectations.  

In spite of this the stock plummeted.  Looking at the chart for the action today, we can see how the stock price hit its low today around 12:25 pm when the price high $47/share.  After that point, the price gradually closed into the close of the day. 

Like so many amateur investors, I really wasn't sure what I should be doing with this stock!  My gut was full of panic and directed me to sell quickly!  Yet my brain screamed out that this was irrational.  That the continued dip on good news was nuts and that I needed instead to buy.

I chose to use my brain and while holding my nose, picked up 150 shares of Haemonetics (HAE) at $48.60/share.  This wasn't really my 'system' at work, but there are times when stock actions defy logic and I hoped this was one of them.

Fortunately, HAE gathered strength into the close and ended up at $49.37, down $(2.67) or (5.13)% on the day.  

Where does HAE go from here?  I don't really know.  But the news released was solid and I chose to add to my small position of HAE making it now my largest holding in my portfolio.


(0)
No Comments
Post Comment
Name:  
Alert for new comments:
Your email:
Your Website:
Title:
Comments:
   
 
 
 
 
   
 

The above story is the opinion of the author only and it does not reflect iStockAnalyst opinion. Further, the author is not personally advising you regarding the suitability of the story for your investment needs. In no event iStockAnalyst will be liable for any loss or damage including without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from or arising out of, or in connection with the use of this information. Please consult your investment advisor before making any investment decision.
  
Advertisement
Popular Articles
Related Press Releases
Advertisement
Partner Center
Recent Articles by Bobs Advice for Stocks



Subscribe to Email Alerts rss feed or RSS feeds rss feed for articles from more than 500 contributors, press releases, SEC filings and full text news from more than four thousand sources.
Fundamental data is provided by Zacks Investment Research, market data is provided by AlphaTrade. , and Commentary and Press Releases provided by Quotemedia